Troglitazone inhibits isolated cell proliferation, and induces apoptosis in isolated rat mesangial cells

American Journal of Nephrology

Volumn 23, Issue 4, 2003, Pages 222-228

  Tsuchiya, Takahumi ^a   Shimizu, Hiroyuki ^a   Shimomura, Kenju ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell proliferation; Mesangial cell; Mitogen activated protein kinase; Peroxyisome proliferator activated receptor gamma; Troglitazone

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BROXURIDINE; DNA FRAGMENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TROGLITAZONE;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; MALE; MESANGIUM CELL; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; APOPTOSIS; BROMODEOXYURIDINE; CELL DIVISION; CELLS, CULTURED; CHROMANS; GLOMERULAR MESANGIUM; HYPOGLYCEMIC AGENTS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0043074753     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072053     Document Type: Article

References (42)

1. Striker LJ, Doi T, Elliot S, Striker GE: The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989;9:318-328.
2. Steffes MW, Osterby R, Chavers B, Mauer SM: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989;38:1077-1081.
3. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 1992;42:647-656.
4. Kikkawa R, Umemura K, Haneda M, Kajiwara N, Maeda S, Nishimura C, Shigeta Y: Identification and characterization of aldose reductase in cultured rat mesangial cells. Diabetes 1992;41:1165-1171.
5. Kikkawa R, Umemura K, Haneda M, Arimura T, Ebata K, Shigeta Y: Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes 1987;36:240-243.
6. Kikkawa R, Haneda M, Uzu T, Koya D, Sugimoto T, Shigeta Y: Translocation of protein kinase C alpha and zeta in rat glomerular mesangial cells cultured under high glucose conditions. Diabetologia 1994;37:838-841.
7. Haneda M, Arai S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-853.
8. Ishii H, Koya D, King GL: Protein kinase C activation and its role in the development of vascular complication in diabetes mellitus. J Mol Med 1998;76:21-31.
9. Koya D, King GL: Protein kinase C activation and the development of diabetic complication. Diabetes 1998;47:859-866.
10. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Gianni S, Cresci B, Galli G, Rotella CM, Vlassara H, Di Mario U: Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997;46:1881-1887.
11. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-1558.
12. Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H: Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism 1991;40:1213-1218.
13. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953-12956.
15. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K, Kondo M: Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 1997;46:981-983.
16. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA: Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hyertension 2001;37:722-727.
17. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M: Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998;21:2135-2139.
18. Asano T, Wakisaka M, Yoshinari M, Iino K, Sonoki K, Iwase M, Fujishima M: Peroxisome proliferator-activated receptor gamma 1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochm Biophys Acta 2000;1497:148-154.
19. Rovin BH, Wilmer WA, Lu L, Doseff AI, Dixon C, Kotur M, Hilbelink T: 15-deoxy-delta 12,14-prostaglandin J2 regulates mesangial cell proliferation and death. Kidney Int 2002;61:1293-1302.
20. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytoxicity assays. J Immunol Methods 1983;65:55-63.
21. Porstmann T, Ternynck T, Avrameas S: Quantification of 5-bromo-2-deoxyuridine incorporation into DNA: An enzyme immunoassay for the assessment of the lymphoid cell proliferative response. J Immunol Methods 1985;82:169-179.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
23. Ezawa K, Minato K, Dobashi K: Induction of apoptosis by ubenimex (Bestatin®) in human non-small-cell lung cancer cell lines. Biomed Pharmacother 1996;50:283-289.
24. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:906-919.
25. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
26. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
27. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 1996;137:354-366.
28. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaighter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker Fatty rats. Diabetes 1998;47:1326-1334.
29. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000;58:1703-1710.
30. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684.
31. Shibata H, Nii S, Kobayashi M: Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: Safety and pharmacokinetics in single administration. Rinsho Iyaku 1993;9:1503-1518.
32. Heilig CW, Liu Y, England RL, Freytag SO, Gilbert JD, Heilig KO, Zhu M, Concepcion LA, Brosius FC 3rd: D-Glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: Implications for diabetic nephropathy. Diabetes 1997;46:1030-1039.
33. Asano T, Wakisaka M, Yoshinari M, Nakamura S, Doi Y, Fujishima M: Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells. Metabolism 2000;49:308-313.
34. Matsuo H, Yamasaki H, Matsumoto K, Uotani S, Yamaguchi Y, Akazawa S, Yamashita S, Nagataki S: Adenosine 3′,5′-cyclic monophosphate mimics the inhibitory effect of high glucose on MAP kinase phosphorylation in rat mesangial cells. Biochem Biophys Res Commun 1996;226:746-754.
35. Sugimoto T, Kikkawa R, Haneda M, Shigeta Y: Atrial natriuretic peptide inhibits endothelin-1-induced activation of mitogen-activated protein kinase in cultured rat mesangial cells. Biochem Biophys Res Commun 1993;195:72-78.
36. Haneda M, Kikkawa R, Sugimoto T, Koya D, Araki S, Togawa M, Shigeta Y: Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J Diab Complications 1995;9:246-248.
37. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998;95:8806-8811.
38. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-139.
39. Hirase N, Yanase T, Mu Y, Muta K, Uemura T, Takayanagi R, Nawata H: Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. Oncology 1999;57(suppl 2):17-26.
40. Ohtani K, Shimizu H, Sato N, Mori M: Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology 1998;139:172-178.
41. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998;101:1354-1361.
42. Conner EA, Teramoto T, Wirth PJ, Kiss A, Garfield S, Thorgeirsson SS: HGF-mediated apoptosis via p53/bax-independent pathway activating JNK1. Carcinogenesis 1999;20:583-590.